Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes

被引：0

作者：

Andre, V. ^{[1
]}

Harbeck, N. ^{[2
]}

Rastogi, P. ^{[3
,4
]}

O'Shaughnessy, J. ^{[5
]}

Boyle, F. ^{[6
]}

Cortes, J.

Rugo, H. S. ^{[7
,8
]}

Goetz, M. P. ^{[9
]}

Hamilton, E. ^{[10
]}

Huang, C. -s.

Senkus, E. ^{[11
]}

Tryakin, A. ^{[12
]}

Neven, P. ^{[13
]}

Huober, J. ^{[14
]}

Wei, R. ^{[1
]}

Munoz, M. ^{[1
]}

Antonio, B. S. ^{[1
]}

Shahir, A. ^{[1
]}

Martin, M. ^{[15
]}

Johnston, S. ^{[16
]}

机构：

[1] Eli Lilly & Co, Indianapolis, IN USA

[2] LMU Univ Hosp, Breast Ctr, Comprehens Canc Ctr Munchen, Dept Gynecol & Obstet, Munich, Germany

[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[4] NSABP Fdn, Pittsburgh, PA USA

[5] Baylor Univ, Texas Oncol, US Oncol, Med Ctr, Dallas, TX USA

[6] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia

[7] Int Breast Canc Ctr IBCC, Quironsalud Grp, Barcelona, Spain

[8] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA USA

[9] Mayo Clin, Rochester, MN USA

[10] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA

[11] Med Univ Gdansk, Gdansk, Poland

[12] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[13] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Louvain, Belgium

[14] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland

[15] Univ Complutense, Hosp Gen Univ Gregorio Maranon, CIBERONC, GEICAM, Madrid, Spain

[16] Royal Marsden NHS Fdn Trust, London, England

来源：

BREAST | 2025年 / 80卷

关键词：

D O I：

10.1016/j.breast.2025.103903

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P009

引用

页数：2

共 50 条

[41] MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis [J].

Goetz, Matthew P. ;

Martin, Miguel ;

Di Leo, Angelo ;

Im, Seock-Ah ;

Awada, Ahmad ;

Forrester, Tammy ;

Frenzel, Martin ;

Cox, Joanne ;

Barriga, Susana ;

Toi, Masakazu ;

Iwata, Hiroji ;

Johnston, Stephen .

CANCER RESEARCH, 2018, 78 (13)

[42] Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer [J].

O'Shaughnessy, Joyce A. ;

Johnston, Stephen ;

Harbeck, Nadia ;

Toi, Masakazu ;

Im, Young-Hyuck ;

Reinisch, Mattea ;

Shao, Zhimin ;

Lehtinen, Pirkko Liisa Kellokumpu ;

Huang, Chiun-Sheng ;

Tryakin, Alexey ;

Goetz, Matthew ;

Rugo, Hope S. ;

Senkus, Elzbieta ;

Testa, Laura ;

Andersson, Michael ;

Tamura, Kenji ;

Steger, Guenther G. ;

Del Mastro, Lucia ;

Cox, Joanne ;

Forrester, Tammy ;

Sherwood, Sarah ;

Li, Xuelin ;

Wei, Ran ;

Martin, Miguel ;

Rastogi, Priya .

CANCER RESEARCH, 2021, 81 (04)

[43] Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial [J].

Rubenstein, C. S. ;

Turner, N. ;

Reis-Filho, J. S. ;

Goetz, M. P. ;

Desmedt, C. ;

Chandarlapaty, S. ;

Sasano, H. ;

Arteaga, C. L. ;

Loi, S. ;

Graff, S. L. ;

Liu, D. ;

Rodrik-Outmezguine, V. ;

Sireci, A. ;

Won, H. ;

Litchfield, L. M. ;

Munoz, M. ;

Johnston, S. .

BREAST, 2025, 80

[44] Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy A Prespecified Analysis of the monarchE Randomized Clinical Trial [J].

Martin, Miguel ;

Hegg, Roberto ;

Kim, Sung-Bae ;

Schenker, Michael ;

Grecea, Daniela ;

Angel Garcia-Saenz, Jose ;

Papazisis, Konstantinos ;

Ouyang, Quchang ;

Lacko, Aleksandra ;

Oksuzoglu, Berna ;

Reeves, James ;

Okera, Meena ;

Testa, Laura ;

Shimizu, Chikako ;

Denduluri, Neelima ;

Adamchuk, Hryhoriy ;

Dakhil, Shaker ;

Wei, Ran ;

Forrester, Tammy ;

Fernandez, Maria Munoz ;

Zimmermann, Annamaria ;

Headley, Desiree ;

Johnston, Stephen R. D. .

JAMA ONCOLOGY, 2022, 8 (08) :1190-1194

[45] MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer [J].

Rastogi, Priya ;

Toi, Masakazu ;

Harbeck, Nadia ;

Bourayou, Nawel ;

Frenzel, Martin ;

Johnston, Stephen .

CANCER RESEARCH, 2018, 78 (04)

[46] Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials [J].

Florence Lerebours ;

Marina Pulido ;

Emmanuelle Fourme ;

Marc Debled ;

Véronique Becette ;

Hervé Bonnefoi ;

Sofia Rivera ;

Gaetan MacGrogan ;

Marie-Ange Mouret-Reynier ;

Christine Tunon de Lara ;

Jean-Yves Pierga ;

Christel Breton-Callu ;

Laurence Venat-Bouvet ;

Simone Mathoulin-Pélissier ;

Thibault de la Motte rouge ;

Florence Dalenc ;

Brigitte Sigal ;

Thomas Bachelot ;

Jérôme Lemonnier ;

Nathalie Quenel-Tueux .

British Journal of Cancer, 2020, 122 :759-765

[47] Bireociclib plus fulvestrant for advanced HR+/HER2- breast cancer progressing after endocrine therapy: Interim analysis of a phase 3 trial (BRIGHT-2) [J].

Wang, Jiayu ;

Zhang, Qingyuan ;

Li, Huiping ;

Tong, Zhongsheng ;

Ouyang, Quchang ;

Li, Huihui ;

Teng, Yuee ;

Wang, Biyun ;

Sun, Tao ;

Wang, Jingfen ;

Li, Wei ;

Niu, Zhaofeng ;

Li, Hongsheng ;

Gong, Chang ;

Wang, Li ;

Liu, Fei ;

Wang, Shuya ;

Meng, Yaping ;

Duan, Xianghui ;

Xu, Binghe .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[48] MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC) [J].

Goetz, M. P. ;

Toi, M. ;

Huober, J. ;

Sohn, J. ;

Tredan, O. ;

Park, I. H. ;

Campone, M. ;

Chen, S. C. ;

Sanchez, L. M. Manso ;

Paluch-Shimon, S. ;

van Hal, G. ;

Shahir, A. ;

Iwata, H. ;

Johnston, S. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S1384-S1384

[49] Real-World Observational Study of Incidence and Outcomes in an HR+/HER2- Early Breast Cancer Population with High-Risk of Recurrence in Finland [J].

Singh, Ravinder ;

Tuominen, Samuli ;

Lassenius, Mariann I. ;

Auvinen, Merja ;

Torstensson, Astrid ;

Wiklund, Tom .

ONCOLOGY AND THERAPY, 2025, 13 (01) :185-200

[50] MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer [J].

Goetz, Matthew ;

Toi, Masakazu ;

Huober, Jens ;

Sohn, Joo Hyuk ;

Tredan, Olivier ;

Park, Inhae ;

Campone, Mario ;

Chen, Shin-Cheh ;

Manso, Luis Manual ;

Paluch-Shimon, Shani ;

Freedman, Orit C. ;

Andre, Valerie ;

Saha, Abhijoy ;

van Hal, Gertjan ;

Shahir, Ashwin ;

Iwata, Hiroji ;

Johnston, Stephen R. D. ;

O'Shaughnessy, Joyce ;

Pivot, Xavier ;

Tolaney, Sara ;

Hurvitz, Sara ;

Llombart, Antonio .

CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 5 →